Navigation Links
Renhuang Pharmaceuticals, Inc. Holds Trade Show for Tianma Pills; Signs Letters of Intent
Date:6/6/2008

HARBIN, China, June 6 /Xinhua-PRNewswire-FirstCall/ -- Renhuang Pharmaceuticals, Inc. (Pink Sheets: RHGP) ("Renhuang" or "the Company"), a leading pharmaceutical company in the People's Republic of China ("PRC"), today announced the successful completion of its Tianma pills trade show in Harbin, China on May 29, 2008.

Tianma pills, one of the Chinese traditional medicines Renhaung manufactories, are approved for the treatment of headaches. The primary active ingredient in Tianma pills, Rhizoma Gastrodiae, is released into the blood stream, supplying nutrients that relax brain nerves and speed up blood circulation. Since Tianma pills are highly effective with no side effects, they are one of the top-selling headache drugs in China by volume.

The trade show attracted about 100 agencies and representatives from major retail chains around the country. Renhuang signed letters of intent for distribution agreements with two separate pharmaceutical retail chain stores: Harbin Renmin Tongtai Pharmaceutical and Baofeng Pharmaceutical. The agreements are expected to bring an additional RMB 20 million in sales for Renhuang. Harbin Renmin Tongtai Pharmaceutical has 57 stores, which are all located in Heilongjiang province. Baofeng Pharmaceutical has over 1000 stores, covering Heilongjiang, Shanghai, Nanjing and Hangzhou.

"We intend to increase our sales growth going forward by focusing on promoting our products through marketing and improving our product pipeline by finding the best product mix," said Mr. Shao-ming Li, Chairman and CEO of Renhaung Pharmaceuticals, Inc. "In addition, we are confident that sales of Tianma pills for Fiscal Year 2008 will surpass sales of $1.97 million recorded in 2007."

About Renhuang Pharmaceuticals, Inc.

Founded in 1996, Renhuang Pharmaceuticals, Inc, produces western, traditional Chinese medicines (TCM), and branded pharmaceuticals, using its GMP-certified facilities in China. The Company's GMP-certified manufacturing facilities, containing cutting-edge technologies and advance equipment, are capable of producing as many as 200 types of pharmaceuticals. Additionally, Renhuang distributes raw materials and finished pharmaceutical products using its extensive distribution channels and third party distributors throughout China. The Company's distribution network includes over 3,000 sales representatives in 70 sales centers across 24 districts, covering over 50% of the greater China. The Company also exports its products to Russia and Southeast Asia. For more information, visit http://www.renhuang.com .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding our future plans, objectives or performance. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

For more information, please contact:

Renhuang Pharmaceuticals, Inc.

Ms. Shuang Tan, IR Contact

Tel: +86-451-5392-5461

Email: ir@renhuang.com

CCG Elite Investor Relations Inc.

Mr. Crocker Coulson, President

Tel: +1-646-213-1915 (New York)

Email: crocker.coulson@ccgir.com

Web: http://www.ccgelite.com


'/>"/>
SOURCE Renhuang Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Renhuang Pharmaceuticals, Inc. Retains CCG Elite
2. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
3. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
4. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
5. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
6. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
7. ACG Announces Major Gift by Salix Pharmaceuticals, Inc.
8. Anthera Pharmaceuticals, Inc. Appoints Donald Santel to Board of Directors
9. Elan Pharmaceuticals, Inc. Licenses Software and Databases From GeneGo
10. Jazz Pharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
11. Acura Pharmaceuticals, Inc. Announces Implementation of Reverse Stock Split and New Trading Symbol: ACPH
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... On June ... sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, ... of the city’s history as home to some of the world’s leading providers of ...
(Date:6/25/2016)... D.C. (PRWEB) , ... June 25, 2016 , ... ... discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, ... their work on several important health care topics including advance care planning, healthcare ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... , June 23, 2016 Bracket , a ... its next generation clinical outcomes platform, Bracket eCOA (SM) ... on June 26 – 30, 2016 in Philadelphia ... electronic Clinical Outcome Assessment product of its kind to fully ... Bracket eCOA 6.0 is a flexible platform for ...
Breaking Medicine Technology: